---
title: "HEARTSCIENCES INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q3 EPS: USD -2.57"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/243364630.md"
datetime: "2025-06-06T01:59:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/243364630.md)
  - [en](https://longbridge.com/en/news/243364630.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/243364630.md)
---

# HEARTSCIENCES INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q3 EPS: USD -2.57

EPS: As of FY2025 Q3, the actual value is USD -2.57.

EBIT: As of FY2025 Q3, the actual value is USD -2.371 M.

### Segment Revenue

-   **Revenue**: The company reported no revenue for the three and nine months ended January 31, 2025, compared to $15,000 and $19,000 for the same periods in 2024, respectively.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended January 31, 2025 was $2.5 million, an increase from $1.6 million in the same period in 2024. For the nine months ended January 31, 2025, the net loss was $6.7 million, compared to $4.8 million in 2024.
-   **Research and Development Expenses**: R&D expenses were $1.0 million for the three months ended January 31, 2025, up from $510,000 in 2024. For the nine months ended January 31, 2025, R&D expenses were $3.5 million, compared to $1.8 million in 2024.
-   **Selling, General and Administrative Expenses**: These expenses were $1.3 million for the three months ended January 31, 2025, up from $1.0 million in 2024. For the nine months ended January 31, 2025, these expenses were $3.0 million, compared to $2.6 million in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: The company used $5.8 million in operating activities during the nine months ended January 31, 2025, compared to $4.5 million in 2024.
-   **Net Cash Used in Investing Activities**: Cash used in investing activities was $22,000 for the nine months ended January 31, 2025, compared to $56,000 in 2024.
-   **Net Cash Provided by Financing Activities**: Financing activities provided $2.6 million during the nine months ended January 31, 2025, compared to $10.0 million in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to seek FDA submission for the MyoVista wavECG in the first half of 2025 and aims for a submission of the MyoVista Insights Cloud Platform and low ejection fraction algorithm in the second half of 2025.
-   **Non-Core Business**: The company is developing a cloud-based platform to host AI-ECG algorithms and has entered into multiple license agreements with Mount Sinai to commercialize AI cardiovascular algorithms.

### Related Stocks

- [HSCSW.US](https://longbridge.com/en/quote/HSCSW.US.md)

## Related News & Research

- [Bitcoin Holders Lose $88,600,000 in Coldcard Crypto Wallet Exploit: Galaxy Researchers](https://longbridge.com/en/news/294653457.md)
- [ROI-OPEC+ oil output hike is irrelevant for now, not for later: Russell](https://longbridge.com/en/news/294620367.md)
- [What's Wrong With Micron Technology Stock?](https://longbridge.com/en/news/294710998.md)
- [ARM Stock: A $1 Billion AGI CPU Opportunity Could End Up Being Much Bigger Than Wall Street Expects](https://longbridge.com/en/news/294711660.md)
- [PREVIEW-SpaceX's first results put Musk's AI spending under Wall Street microscope](https://longbridge.com/en/news/294675458.md)